Patents by Inventor Francesc Mitjans
Francesc Mitjans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220196650Abstract: The present invention provides a sensor comprising at least one whispering gallery mode resonator, wherein the resonator comprises a Bragg grating arranged over at least a portion of the perimeter of the resonator and wherein the resonator is selectively functionalized for the attachment of analyte receptors.Type: ApplicationFiled: April 29, 2020Publication date: June 23, 2022Inventors: Francesc Mitjans Prat, Laura Padilla García, Gregory Kozyreff, Nirmalendu Acharyya, Michiel De Goede, Lantian Chang, Meindert Dijkstra, Sonia M. Garcia Blanco, Javier Ramón Azcón, Raquel Obregón Núñez, Elena Martínez Fraiz, Johann Toudert, Jordi Martorell Pena, Veselin Brankovic, Veljko Mihajlovic, Marko Parausic, Darko Tasovac
-
Patent number: 9914768Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.Type: GrantFiled: April 9, 2014Date of Patent: March 13, 2018Assignee: Lykera Biomed, S.A.Inventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 9868784Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: GrantFiled: December 7, 2015Date of Patent: January 16, 2018Assignee: LYKERA BIOMED SAInventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 9657092Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: GrantFiled: November 25, 2014Date of Patent: May 23, 2017Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Publication number: 20160289307Abstract: The present invention relates to the use of antibodies against S100A7 protein for the prevention and/or treatment of cancer or a disease associated to an undesired angiogenesis or a disease associated with inflammation; and to methods and kits for diagnosing and determining the prognostic of said diseases in vitro and in vivo by means of detecting levels of S100A7 in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100A7 monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as pharmaceutical compositions and conjugates containing them.Type: ApplicationFiled: April 9, 2014Publication date: October 6, 2016Applicant: LYKERA BIOMED SAInventors: José Luis HERNÁNDEZ MÍGUEZ, Jaume ADAN PLANA, Josep Maria MARTÍNEZ ESCOLÀ, Marc MASA ÁL VAREZ, Ramon MESSEGUER PEYPOCH, Francesc MITJANS PRAT, Sheila DAKHEL PLAZA, Antonio COLL MANZANO, Rosa Mª HERVAS VILLEGAS, Carme CALVIS CALPE, Laura PADILLA GARCÍA, Lourdes Tatiana ROQUE NAVARRO, Laura BARBERÀ FERRANDO, Manuel RIVAS CANAS
-
Publication number: 20160090412Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: ApplicationFiled: December 7, 2015Publication date: March 31, 2016Inventors: José Luis HERNÁNDEZ MÍGUEZ, Jaume ADAN PLANA, Josep Maria MARTÍNEZ ESCOLÀ, Marc MASA ÁLVAREZ, Ramon MESSEGUER PEYPOCH, Francesc MITJANS PRAT, Sheila DAKHEL PLAZA, Antonio COLL MANZANO, Rosa Mª HERVAS VILLEGAS, Carme CALVIS CALPE, Laura PADILLA GARCÍA, Lourdes Tatiana ROQUE NAVARRO, Laura BARBERÀ FERRANDO, Manuel RIVAS CAÑAS
-
Patent number: 9228011Abstract: The present invention relates to the use of antibodies against the S100P protein for the prevention and/or treatment of cancer; and to methods and kits for diagnosing cancer in vitro by means of detecting the levels of S100P in a biofluid, preferably with an antibody. The invention also relates to specific anti-S100P monoclonal antibodies, hybridoma cell lines producing them and method for obtaining them, as well as to pharmaceutical compositions and conjugates containing them.Type: GrantFiled: January 17, 2012Date of Patent: January 5, 2016Assignee: Lykera Biomed SAInventors: José Luis Hernández Míguez, Jaume Adan Plana, Josep Maria Martínez Escolà, Marc Masa Álvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla García, Lourdes Tatiana Roque Navarro, Laura Barberà Ferrando, Manuel Rivas Cañas
-
Patent number: 8993261Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.Type: GrantFiled: March 15, 2013Date of Patent: March 31, 2015Assignee: Merck Patent GmbHInventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
-
Publication number: 20150079097Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Patent number: 8916152Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: GrantFiled: June 14, 2011Date of Patent: December 23, 2014Assignee: Lykera Biomed SAInventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Patent number: 8562986Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.Type: GrantFiled: July 17, 2008Date of Patent: October 22, 2013Assignee: Merck Patent GmbHInventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
-
Publication number: 20130101592Abstract: The invention relates to antibodies against S100A4, methods for the preparation of these antibodies, pharmaceutical compositions comprising these antibodies, and therapeutic and diagnostic uses thereof.Type: ApplicationFiled: June 14, 2011Publication date: April 25, 2013Applicant: LYKERA BIOMED SAInventors: Jose Luis Hernandez Miguez, Jaume Adan Plana, Josep Maria Martinez Escola, Marc Masa Alvarez, Ramon Messeguer Peypoch, Francesc Mitjans Prat, Sheila Dakhel Plaza, Antonio Coll Manzano, Rosa Ma Hervas Villegas, Carme Calvis Calpe, Laura Padilla Garcia, Lourdes Tatiana Roque Navarro, Laura Barbera Ferrando, Manuel Rivas Canas, Luis Angel Gomez Casajus
-
Patent number: 8420348Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.Type: GrantFiled: July 15, 2010Date of Patent: April 16, 2013Assignee: Merck Patent Gesellschaft Mit Beschrankter HaftungInventors: Simon Goodman, Claudia Wilm, Francesc Mitjans
-
Publication number: 20100254977Abstract: The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.Type: ApplicationFiled: July 17, 2008Publication date: October 7, 2010Applicant: MERCK PATENT GMBHInventors: Simon Goodman, Diane Hahn, Francesc Mitjans, Jaume Adan, Kin-Ming Lo
-
Patent number: 7547695Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.Type: GrantFiled: October 14, 2004Date of Patent: June 16, 2009Assignee: Merck Patent GmbHInventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
-
Publication number: 20070225347Abstract: Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X? have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.Type: ApplicationFiled: March 15, 2005Publication date: September 27, 2007Applicant: Merck Patent GmbHInventors: Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Arne Sutter, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Riera
-
Publication number: 20070099910Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.Type: ApplicationFiled: October 14, 2004Publication date: May 3, 2007Applicant: Merck Patent GmbHInventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
-
Publication number: 20070021456Abstract: Novel compounds of formula (I) are disclosed, where R1, R1?, L, Y, m and p have the meanings given in claim 1, which are inhibitors of tyrosine kinases, in particular, TIE-2 and Raf kinases and can be used for the treatment of tumors.Type: ApplicationFiled: July 19, 2004Publication date: January 25, 2007Applicant: MERCK PATENT GMBHInventors: Francesc Mitjans, Elisabet Rosel-Vives, Jaume Adan, Marta Soler, Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg
-
Publication number: 20060241301Abstract: The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.Type: ApplicationFiled: July 2, 2004Publication date: October 26, 2006Inventors: Gunter Hoelzemann, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Helerie Crassier, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
-
Patent number: 5985278Abstract: The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.Type: GrantFiled: December 19, 1995Date of Patent: November 16, 1999Assignee: Merck Patent Gesellschaft mit Beschrankter HaftungInventors: Francesc Mitjans, Jaume Piulats, Elisabet Rosell, Jaume Adan, Simon Goodman, Diane Hahn